People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study

被引:2
|
作者
Conway, Anna [1 ,2 ]
Treloar, Carla [2 ]
Crawford, Sione [3 ]
Grebely, Jason [1 ]
Marshall, Alison D. [1 ,2 ]
机构
[1] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia
[2] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia
[3] Harm Reduct Victoria, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
Big Event; counterpublic; peers; practises of care; substance use; HEPATITIS-C; HEALTH; BARRIERS;
D O I
10.1111/dar.13531
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction People receiving opioid agonist treatment (OAT) are at higher risk of comorbidities, poverty and discrimination, which Big Events like the COVID-19 pandemic may exacerbate. The behaviours of people receiving OAT do not always align with normative behaviours as conceived by ruling institutions and laws, and so the group becomes a counterpublic, not imagined in mainstream public discourse. The aim of this study was to understand how people receiving OAT, as a counterpublic, implemented practises of care to mitigate negative health outcomes during COVID-19. Methods Participants were recruited via eight peer-led organisations across Australia. In-depth, semi-structured interviews were completed between August and December 2020 with 40 people receiving OAT. The analysis centres practises of care, allowing interactions that influence the health of participants, to be understood in their unique contexts. Results Aspects of the COVID-19 state response were designed for an idealised public, demonstrated by the increased policing that accompanied enforcement of restrictions which was detrimental to the wellbeing of people receiving OAT. Counterpublic health strategies employed by people receiving OAT were disrupted, but participants were often able to adapt to the changing context. Discussion and Conclusion This study elucidates how practises of care among people receiving OAT are enacted and disrupted during a Big Event, with implications beyond the COVID-19 pandemic for future Big Events. The study findings evidence the need for policies that mitigate the impact of Big Events such as supporting re-groupment within the counterpublic, legitimising counterpublic health strategies and stopping the criminalisation of people who use drugs.
引用
收藏
页码:203 / 212
页数:10
相关论文
共 50 条
  • [21] A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report
    Des Crowley
    Ide Delargy
    Harm Reduction Journal, 17
  • [22] Bronchiectasis cough during the COVID-19 pandemic: a qualitative study
    Blamires, Julie
    Foster, Mandie
    Mcrae, Wendy
    Mooney, Sarah
    NEW ZEALAND MEDICAL JOURNAL, 2025, 138 (1609) : 86 - 97
  • [23] Remote primary care during the COVID-19 pandemic for people experiencing homelessness: a qualitative study
    Howells, Kelly
    Amp, Mat
    Burrows, Martin
    Brown, Jo
    Brennan, Rachel
    Dickinson, Joanne
    Jackson, Shaun
    Yeung, Wan-Ley
    Ashcroft, Darren
    Campbell, Stephen
    Blakeman, Thomas
    Sanders, Caroline
    BRITISH JOURNAL OF GENERAL PRACTICE, 2022, : E492 - E500
  • [24] Involuntary psychiatric treatment during the COVID-19 pandemic. An international qualitative study
    Carbone, Agostino
    Knapp, Martin
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [25] Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy
    Soroush Moallef
    Kora DeBeck
    Nadia Fairbairn
    Zishan Cui
    Rupinder Brar
    Dean Wilson
    Cheyenne Johnson
    M.-J. Milloy
    Kanna Hayashi
    Addiction Science & Clinical Practice, 17
  • [26] Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy
    Moallef, Soroush
    DeBeck, Kora
    Fairbairn, Nadia
    Cui, Zishan
    Brar, Rupinder
    Wilson, Dean
    Johnson, Cheyenne
    Milloy, M. -J.
    Hayashi, Kanna
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2022, 17 (01)
  • [27] Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation
    Lott, Aline M.
    Danner, Anissa N.
    Malte, Carol A.
    Williams, Emily C.
    Gordon, Adam J.
    Halvorson, Max A.
    Saxon, Andrew J.
    Hagedorn, Hildi J.
    Sayre, George G.
    Hawkins, Eric J.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (04) : E262 - E268
  • [28] A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19
    Lockard, Rachel
    Priest, Kelsey C.
    Gregg, Jessica
    Buchheit, Bradley M.
    SUBSTANCE ABUSE, 2022, 43 (01) : 1150 - 1157
  • [29] Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
    Bouck, Zachary
    Scheim, Ayden I.
    Gomes, Tara
    Ling, Vicki
    Caudarella, Alexander
    Werb, Dan
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 104
  • [30] Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
    Morin, Kristen A.
    Acharya, Shreedhar
    Eibl, Joseph K.
    Marsh, David C.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 90